Go to content
OctoPlus N.V.

OctoPlus N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 13 mrt 2012 - 22:39
Statutaire naam OctoPlus N.V.
Titel OctoPlus announces agreement with top-5 generics company for the development of a specialty generic
Bericht OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces today that it has signed a feasibility agreement with a top-5 generics company to develop a generic formulation of an existing injectable specialty pharmaceutical product. Under the terms of the contract that was announced earlier today, OctoPlus will develop up to the phase of preparation for small-scale production, a generic copy of one of the major injectable specialty pharmaceuticals. If the project is successful, the contract may progress to a full process development and manufacturing agreement. Financial terms of the current agreement have not been disclosed.